A Study of ZN-c3 and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer
Status:
Not yet recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1/2 study to evaluate the safety, clinical activity, pharmacokinetics (PK),
and pharmacodynamics (PD) of ZN-c3 in combination with niraparib in subjects with
platinum-resistant ovarian cancer.